Literature DB >> 9313947

Central benzodiazepine receptor autoradiography in hippocampal sclerosis.

K S Hand1, V H Baird, W Van Paesschen, M J Koepp, T Revesz, M Thom, W F Harkness, J S Duncan, N G Bowery.   

Abstract

1. The gamma-aminobutyric acid (GABA)A/central benzodiazepine receptor (cBZR) complex is a major inhibitory receptor in the vertebrate CNS. Binding of [11C]-flumazenil to this complex in vivo is reduced in hippocampal sclerosis (HS). It has been uncertain whether reduced cBZR binding is entirely due to neuronal loss in HS. 2. The objective of this study was to characterize abnormalities of the cBZR in HS with a correlative autoradiographic and quantitative neuropathological study. 3. Saturation autoradiographic studies were performed with [3H]-flumazenil to investigate relationships between neuronal density and receptor availability (Bmax) and affinity (Kd) in HS. Hippocampal tissue was obtained at surgery from 8 patients with intractable temporal lobe epilepsy (TLE) due to HS and autopsies of 6 neurologically normal controls. Neuronal densities were obtained by means of a 3-D counting method. 4. Bmax values for [3H]-flumazenil binding in the subiculum, CA1, CA2, CA3, hilus and dentate gyrus were all found to be significantly reduced in HS compared with controls and significant increases in affinity were observed in the subiculum, hilus and dentate gyrus. In HS, cBZR density in the CA1 region was significantly reduced (P < 0.05) to a greater extent than could be attributable to neurone loss. In other regions, Bmax was reduced in parallel with neuronal density. 5. In HS, there is a loss of cBZR in CA1 over and above loss of neurones. This finding and increases in affinity for flumazenil in subiculum, hilus and dentate gyrus imply a functional abnormality of the GABAA/cBZR complex that may have a role in the pathophysiology of epileptogenicity in HS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9313947      PMCID: PMC1564922          DOI: 10.1038/sj.bjp.0701365

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  GABA(B) receptor autoradiography in hippocampal sclerosis associated with human temporal lobe epilepsy.

Authors:  A Billinton; V H Baird; M Thom; J S Duncan; N Upton; N G Bowery
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy.

Authors:  F Loup; H G Wieser; Y Yonekawa; A Aguzzi; J M Fritschy
Journal:  J Neurosci       Date:  2000-07-15       Impact factor: 6.167

Review 3.  Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus.

Authors:  Richard J Burman; Richard E Rosch; Jo M Wilmshurst; Arjune Sen; Georgia Ramantani; Colin J Akerman; Joseph V Raimondo
Journal:  Nat Rev Neurol       Date:  2022-05-10       Impact factor: 44.711

Review 4.  Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures.

Authors:  Tarek Z Deeb; Jamie Maguire; Stephen J Moss
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

5.  Increases in [3H]muscimol and [3H]flumazenil binding in the dorsolateral prefrontal cortex in schizophrenia are linked to α4 and γ2S mRNA levels respectively.

Authors:  Mathieu Verdurand; Stu G Fillman; Cynthia Shannon Weickert; Katerina Zavitsanou
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

6.  In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors:  Lucy Vivash; Marie-Claude Gregoire; Viviane Bouilleret; Alexis Berard; Catriona Wimberley; David Binns; Peter Roselt; Andrew Katsifis; Damian E Myers; Rodney J Hicks; Terence J O'Brien; Stefanie Dedeurwaerdere
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.